AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 11311100 — intervention group
Group type: EXPERIMENTAL
Intervention: Isolated IGT
Number of subjects: 1342
Study 11311100 — intervention group
Group type: EXPERIMENTAL
Intervention: Both IFG and IGT
Number of subjects: 1342
Study 11311100 — intervention group
Group type: EXPERIMENTAL
Intervention: Waist-hip ratio
Number of subjects: 1342
Study 11311100 — intervention group
Group type: EXPERIMENTAL
Intervention: Fasting plasma glucose (FPG)
Number of subjects: 1342
Study 11311100 — intervention group
Group type: EXPERIMENTAL
Intervention: 2-hour postload glucose levels
Number of subjects: 1342
Study 31387158 — intervention group
Group type: EXPERIMENTAL
Intervention: Nasal high flow (NHF) during exercise
Number of subjects: 19
Study 30120812 — intervention group
Group type: EXPERIMENTAL
Intervention: Liraglutide
Number of subjects: 300
Study 30120812 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 300
Study 27412814 — intervention group
Group type: EXPERIMENTAL
Intervention: PNA FISH
Number of subjects: 220
Study 25456960 — intervention group
Group type: EXPERIMENTAL
Intervention: Acupuncture (Electroacupuncture)
Number of subjects: 121
Study 25456960 — intervention group
Group type: EXPERIMENTAL
Intervention: Acupuncture (Traditional Acupuncture)
Number of subjects: 121
Study 25456960 — intervention group
Group type: COMPARATOR
Intervention: Control (Standard postoperative analgesic treatment with acetaminophen)
Number of subjects: 121
Study 23364039 — intervention group
Group type: EXPERIMENTAL
Intervention: Recreational combination gymnastics program (conducted twice a week for 12 weeks)
Number of subjects: 53
Study 20425851 — intervention group
Group type: EXPERIMENTAL
Intervention: Tobramycin solution for inhalation (TSI), 5 ml nebulized treatment twice a day for 28 days (one cycle), followed by 28 days off, for three cycles.
Number of subjects: 32
Study 20425851 — intervention group
Group type: COMPARATOR
Intervention: Placebo group
Number of subjects: 32
Study 17681169 — intervention group
Group type: EXPERIMENTAL
Intervention: Hepatic venous pressure gradient (HVPG)
Number of subjects: 213
Study 17681169 — intervention group
Group type: EXPERIMENTAL
Intervention: Model of end-stage liver disease (MELD)
Number of subjects: 213
Study 17681169 — intervention group
Group type: EXPERIMENTAL
Intervention: Albumin
Number of subjects: 213
Study 15739091 — intervention group
Group type: EXPERIMENTAL
Intervention: Local anesthetics (group 2, n=17)
Number of subjects: 35
Study 15739091 — intervention group
Group type: COMPARATOR
Intervention: 5 ml saline (group 1, n=18)
Number of subjects: 35
Study 12090575 — intervention group
Group type: EXPERIMENTAL
Intervention: Laparoscopic repair
Number of subjects: 7161
Study 12090575 — intervention group
Group type: COMPARATOR
Intervention: Open non-mesh repair
Number of subjects: 7161
Study 12090575 — intervention group
Group type: COMPARATOR
Intervention: Open mesh methods
Number of subjects: 7161
Study 9682119 — intervention group
Group type: EXPERIMENTAL
Intervention: Latanoprost 0.005% (1.5 micrograms)
Number of subjects: 103
Study 9682119 — intervention group
Group type: COMPARATOR
Intervention: Placebo (BSS)
Number of subjects: 103
Study 9682119 — intervention group
Group type: COMPARATOR
Intervention: Both groups (Latanoprost and Control)
Number of subjects: 103
Study 8590488 — intervention group
Group type: EXPERIMENTAL
Intervention: Ketamine (2 mg.kg‐1)
Number of subjects: 30
Study 8590488 — intervention group
Group type: EXPERIMENTAL
Intervention: Midazolam (0.3 mg.kg‐1)
Number of subjects: 30
Study 1967418 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-dose bradykinin infusion (30 ng/kg per min)
Number of subjects: 24
Study 1967418 — intervention group
Group type: EXPERIMENTAL
Intervention: Chronic bradykinin administration (6 days)
Number of subjects: 24
Study 1967418 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 24
Study 279137 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.5% sodium fluoride solution (weekly mouth-rinsings)
Number of subjects: 58
Study 279137 — intervention group
Group type: COMPARATOR
Intervention: Untreated control group
Number of subjects: 58
Study 31931509 — intervention group
Group type: EXPERIMENTAL
Intervention: Nicotine (2-mg lozenge)
Number of subjects: 0
Study 31931509 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 31284833 — intervention group
Group type: EXPERIMENTAL
Intervention: 2D illustrations
Number of subjects: 41
Study 31284833 — intervention group
Group type: EXPERIMENTAL
Intervention: 3D-printed models
Number of subjects: 41
Study 31284833 — intervention group
Group type: COMPARATOR
Intervention: Overall educational outcome
Number of subjects: 41
Study 29042392 — intervention group
Group type: EXPERIMENTAL
Intervention: Empagliflozin (25 mg)
Number of subjects: 34
Study 29042392 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 34
Study 25889057 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive tests administered in a familiar environment (Familiar cohort)
Number of subjects: 9
Study 25889057 — intervention group
Group type: COMPARATOR
Intervention: Cognitive tests administered in a foreign environment (Foreign cohort)
Number of subjects: 9
Study 25889057 — intervention group
Group type: EXPERIMENTAL
Intervention: Caregiver reports for both cohorts
Number of subjects: 9
Study 23427930 — intervention group
Group type: EXPERIMENTAL
Intervention: Pelvic girdle pain (PGP)
Number of subjects: 27
Study 22007904 — intervention group
Group type: EXPERIMENTAL
Intervention: Adapalene gel and nadifloxacin cream
Number of subjects: 50
Study 22007904 — intervention group
Group type: COMPARATOR
Intervention: Adapalene gel monotherapy
Number of subjects: 50
Study 19797187 — intervention group
Group type: EXPERIMENTAL
Intervention: Telmisartan (80 mg/d)
Number of subjects: 1360
Study 19797187 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1360
Study 16825271 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral magnesium 15 mmol twice daily (n = 28)
Number of subjects: 53
Study 16825271 — intervention group
Group type: COMPARATOR
Intervention: Placebo (n = 25)
Number of subjects: 53
Study 12868253 — intervention group
Group type: EXPERIMENTAL
Intervention: Fennel seed oil emulsion
Number of subjects: 125
Study 12868253 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 125
Study 9862830 — intervention group
Group type: EXPERIMENTAL
Intervention: GLP-1 infusion (0, 0.375, 0.75, and 1.5 pmol/kg/min)
Number of subjects: 16
Study 9862830 — intervention group
Group type: EXPERIMENTAL
Intervention: GLP-1 infusion (highest dose)
Number of subjects: 16
Study 8549029 — intervention group
Group type: EXPERIMENTAL
Intervention: Atovaquone (750 mg every 12 hours)
Number of subjects: 14
Study 1834003 — intervention group
Group type: EXPERIMENTAL
Intervention: Warfarin
Number of subjects: 7
Study 1834003 — intervention group
Group type: COMPARATOR
Intervention: Aspirin
Number of subjects: 7
Study 1834003 — intervention group
Group type: COMPARATOR
Intervention: Warfarin and Aspirin
Number of subjects: 7
Study 6800440 — intervention group
Group type: EXPERIMENTAL
Intervention: Preseasonal hyposensitisation treatment with an aqueous rye extract
Number of subjects: 20
Study 6800440 — intervention group
Group type: COMPARATOR
Intervention: Placebo injections
Number of subjects: 20
Study 31424665 — intervention group
Group type: EXPERIMENTAL
Intervention: Endoscopic mucosal resection (EMR)
Number of subjects: 120
Study 31424665 — intervention group
Group type: COMPARATOR
Intervention: Radical surgery
Number of subjects: 120
Study 31424665 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 120
Study 28004259 — intervention group
Group type: EXPERIMENTAL
Intervention: Multifaceted intervention (psycho-education, motivational interviewing, and short message services)
Number of subjects: 288
Study 28004259 — intervention group
Group type: COMPARATOR
Intervention: Treatment-as-usual (TAU)
Number of subjects: 288
Study 26697176 — intervention group
Group type: EXPERIMENTAL
Intervention: Ranolazine (500 mg, uptitrated to 1,000 mg at week 4)
Number of subjects: 12
Study 26697176 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study 23452432 — intervention group
Group type: EXPERIMENTAL
Intervention: Prediction model for OTC-medication use based on maternal characteristics
Number of subjects: 1246
Study 21488067 — intervention group
Group type: EXPERIMENTAL
Intervention: Filibuvir 100 mg twice daily
Number of subjects: 0
Study 21488067 — intervention group
Group type: EXPERIMENTAL
Intervention: Filibuvir 700 mg twice daily
Number of subjects: 0
Study 21488067 — intervention group
Group type: EXPERIMENTAL
Intervention: Filibuvir 450 mg twice daily
Number of subjects: 0
Study 21488067 — intervention group
Group type: COMPARATOR
Intervention: Filibuvir (various doses)
Number of subjects: 0
Study 19479489 — intervention group
Group type: EXPERIMENTAL
Intervention: Estradiol 0.014 mg/day
Number of subjects: 165
Study 19479489 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 165
Study 16537662 — intervention group
Group type: EXPERIMENTAL
Intervention: Candesartan (Atacand, AstraZeneca) for two years
Number of subjects: 772
Study 16537662 — intervention group
Group type: COMPARATOR
Intervention: Placebo for two years
Number of subjects: 772
Study 16537662 — intervention group
Group type: EXPERIMENTAL
Intervention: Candesartan (Atacand, AstraZeneca) for four years
Number of subjects: 772
Study 16537662 — intervention group
Group type: COMPARATOR
Intervention: Placebo for four years
Number of subjects: 772
Study 16537662 — intervention group
Group type: EXPERIMENTAL
Intervention: Candesartan (Atacand, AstraZeneca)
Number of subjects: 772
Study 16537662 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 772
Study 12741670 — intervention group
Group type: EXPERIMENTAL
Intervention: Manipulated cognitive sets of raters (dimensional vs categorical)
Number of subjects: 0
Study 12741670 — intervention group
Group type: COMPARATOR
Intervention: Rating scale measures
Number of subjects: 0
Study 11112084 — intervention group
Group type: EXPERIMENTAL
Intervention: Tacrolimus
Number of subjects: 70
Study 11112084 — intervention group
Group type: COMPARATOR
Intervention: Cyclosporine
Number of subjects: 70
Study 9759389 — intervention group
Group type: EXPERIMENTAL
Intervention: Mitomycin C (0.02 mg/ml, three times daily for 5 days)
Number of subjects: 36
Study 9759389 — intervention group
Group type: EXPERIMENTAL
Intervention: Thio-tepa (four times daily for 6 weeks)
Number of subjects: 36
Study 9759389 — intervention group
Group type: COMPARATOR
Intervention: Distilled water (three times daily for 5 days)
Number of subjects: 36
Study 7812727 — intervention group
Group type: EXPERIMENTAL
Intervention: Na-PMP (2(‐4‐methoxyphenoxy)propanoic acid sodium salt)
Number of subjects: 0
Study 2900187 — intervention group
Group type: EXPERIMENTAL
Intervention: Somatostatin (SRIF) 4 micrograms/kg injected before cannulation
Number of subjects: 33
Study 2900187 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 33
Study 29747618 — intervention group
Group type: EXPERIMENTAL
Intervention: Multimodal school-based stepped-prevention program for depression and suicidal behaviors
Number of subjects: 0
Study 29747618 — intervention group
Group type: COMPARATOR
Intervention: Screening and safety net of gatekeepers at schools (Control)
Number of subjects: 0
Study 28061767 — intervention group
Group type: EXPERIMENTAL
Intervention: Prostaglandin
Number of subjects: 368
Study 28061767 — intervention group
Group type: COMPARATOR
Intervention: No prostaglandin (amniotomy and/or oxytocin)
Number of subjects: 368
Study 28061767 — intervention group
Group type: COMPARATOR
Intervention: Prostaglandin and No prostaglandin
Number of subjects: 368
Study 26171392 — intervention group
Group type: EXPERIMENTAL
Intervention: Intra-articular bupivacaine combined with intravenous parecoxib
Number of subjects: 36
Study 26171392 — intervention group
Group type: COMPARATOR
Intervention: Intravenous parecoxib monotherapy (control group)
Number of subjects: 36
Study 23919274 — intervention group
Group type: EXPERIMENTAL
Intervention: Celecoxib (400 mg twice daily) and UDCA (1000-2000 mg daily, 20-30 mg/kg/day)
Number of subjects: 37
Study 23919274 — intervention group
Group type: COMPARATOR
Intervention: Celecoxib and placebo
Number of subjects: 37
Study 23919274 — intervention group
Group type: COMPARATOR
Intervention: Comparison between celecoxib/UDCA and celecoxib/placebo
Number of subjects: 37
Study 23919274 — intervention group
Group type: EXPERIMENTAL
Intervention: Celecoxib and UDCA
Number of subjects: 37
Study 21179434 — intervention group
Group type: EXPERIMENTAL
Intervention: Mass azithromycin treatment
Number of subjects: 12
Study 21179434 — intervention group
Group type: COMPARATOR
Intervention: No antibiotic treatment (Control)
Number of subjects: 12
Study 18375998 — intervention group
Group type: COMPARATOR
Intervention: Abciximab infusion
Number of subjects: 745
Study 18375998 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose bolus tirofiban
Number of subjects: 745
Study 18375998 — intervention group
Group type: COMPARATOR
Intervention: Uncoated stents
Number of subjects: 745
Study 18375998 — intervention group
Group type: EXPERIMENTAL
Intervention: Sirolimus-eluting stents
Number of subjects: 745
Study 16801929 — intervention group
Group type: EXPERIMENTAL
Intervention: Contingent reinforcement for each fruit and vegetable serving consumed during lunch
Number of subjects: 6
Study 16801929 — intervention group
Group type: COMPARATOR
Intervention: Non-contingent reinforcement irrespective of food intake
Number of subjects: 6
Study 12113544 — intervention group
Group type: EXPERIMENTAL
Intervention: Gabexate mesilate (GM), 2.0 mg/kg/hr, administered intravenously starting 24 hours before surgery until postoperative day 3 (preop GM group)
Number of subjects: 66
Study 12113544 — intervention group
Group type: EXPERIMENTAL
Intervention: Gabexate mesilate (GM), administered at the beginning of surgery (intraop GM group)
Number of subjects: 66
Study 12113544 — intervention group
Group type: COMPARATOR
Intervention: Control group (without GM)
Number of subjects: 66
Study 10458715 — intervention group
Group type: EXPERIMENTAL
Intervention: Dual-chamber pacing (pacing-on)
Number of subjects: 9
Study 10458715 — intervention group
Group type: COMPARATOR
Intervention: Pacing-off
Number of subjects: 9
Study 10458715 — intervention group
Group type: EXPERIMENTAL
Intervention: Dobutamine stimulation after 1 year
Number of subjects: 9
Study 7796558 — intervention group
Group type: EXPERIMENTAL
Intervention: Glucomannan with a 1.200 kcal diet
Number of subjects: 30
Study 7796558 — intervention group
Group type: COMPARATOR
Intervention: Placebo with a 1.200 kcal diet
Number of subjects: 30
Study 2368745 — intervention group
Group type: EXPERIMENTAL
Intervention: Drug-use review (DUR) program intervention
Number of subjects: 288
Study 2368745 — intervention group
Group type: COMPARATOR
Intervention: Control group (no mailing)
Number of subjects: 288
Study 627704 — intervention group
Group type: EXPERIMENTAL
Intervention: Sodium fluoride
Number of subjects: 0
Study 627704 — intervention group
Group type: EXPERIMENTAL
Intervention: Inorganic phosphate
Number of subjects: 0
Study 627704 — intervention group
Group type: EXPERIMENTAL
Intervention: Oxymetholone
Number of subjects: 0
Study 627704 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 6196006 — intervention group
Group type: EXPERIMENTAL
Intervention: ancrod (group B)
Number of subjects: 30
Study 6196006 — intervention group
Group type: COMPARATOR
Intervention: low‐molecular weight dextran and mannitol (group A)
Number of subjects: 30
Study 31591708 — intervention group
Group type: EXPERIMENTAL
Intervention: PRIME designated studies
Number of subjects: 138
Study 31591708 — intervention group
Group type: COMPARATOR
Intervention: Non-PRIME designated products
Number of subjects: 138
Study 29653652 — intervention group
Group type: EXPERIMENTAL
Intervention: Betrixaban for 35-42 days
Number of subjects: 7513
Study 29653652 — intervention group
Group type: EXPERIMENTAL
Intervention: Betrixaban (80 mg)
Number of subjects: 7513
Study 29653652 — intervention group
Group type: COMPARATOR
Intervention: Enoxaparin for 6-14 days
Number of subjects: 7513
Study 26271300 — intervention group
Group type: EXPERIMENTAL
Intervention: Coder reviewed results of a recent ecological assessment
Number of subjects: 46
Study 26271300 — intervention group
Group type: COMPARATOR
Intervention: No ecological assessment information provided to coder
Number of subjects: 46
Study 23417666 — intervention group
Group type: EXPERIMENTAL
Intervention: Fast Track multi‐component preventive intervention
Number of subjects: 1199
Study 23417666 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 1199
Study 22464802 — intervention group
Group type: COMPARATOR
Intervention: Control diet + supplement
Number of subjects: 8
Study 19417194 — intervention group
Group type: EXPERIMENTAL
Intervention: Housing and case management program
Number of subjects: 407
Study 19417194 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 407
Study 17901014 — intervention group
Group type: EXPERIMENTAL
Intervention: Occupation-focused, client-centered occupational therapy
Number of subjects: 16
Study 17901014 — intervention group
Group type: COMPARATOR
Intervention: No-treatment control group
Number of subjects: 16
Study 16301247 — intervention group
Group type: EXPERIMENTAL
Intervention: Atracurium
Number of subjects: 0
Study 16301247 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 11879528 — intervention group
Group type: EXPERIMENTAL
Intervention: Simvastatin 20 mg
Number of subjects: 24
Study 11879528 — intervention group
Group type: EXPERIMENTAL
Intervention: Simvastatin 40 mg
Number of subjects: 24
Study 11879528 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 24
Study 10668106 — intervention group
Group type: EXPERIMENTAL
Intervention: Fixed repetition rate and 30 Hz low pass filter
Number of subjects: 22
Study 10668106 — intervention group
Group type: EXPERIMENTAL
Intervention: Randomly varied stimulus repetition rate and 100 Hz low pass filter
Number of subjects: 22
Study 10668106 — intervention group
Group type: EXPERIMENTAL
Intervention: 1 h retest
Number of subjects: 22
Study 10668106 — intervention group
Group type: EXPERIMENTAL
Intervention: 2-h retest
Number of subjects: 22
Study 10668106 — intervention group
Group type: EXPERIMENTAL
Intervention: 24-h retest
Number of subjects: 22
Study 8652236 — intervention group
Group type: EXPERIMENTAL
Intervention: rhGM-CSF
Number of subjects: 35
Study 8652236 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 35
Study 2087329 — intervention group
Group type: EXPERIMENTAL
Intervention: Needle acupuncture (stainless steel needles at point Hegu (L.I.4) on both sides)
Number of subjects: 79
Study 2087329 — intervention group
Group type: COMPARATOR
Intervention: Laser acupuncture (helium-neon laser at points Hegu (L.I.4) and Jianqian (Extra.) on both sides for 1 min)
Number of subjects: 79
Study 390674 — intervention group
Group type: EXPERIMENTAL
Intervention: Tiaprofenic acid, 200 mg three times a day
Number of subjects: 41
Study 390674 — intervention group
Group type: COMPARATOR
Intervention: Ibuprofen, 400 mg three times a day
Number of subjects: 41
Study 31965072 — intervention group
Group type: EXPERIMENTAL
Intervention: Liraglutide (1.8 mg/d)
Number of subjects: 40
Study 31965072 — intervention group
Group type: COMPARATOR
Intervention: Lifestyle counseling (dietary intervention and exercise training)
Number of subjects: 40
Study 31568698 — intervention group
Group type: EXPERIMENTAL
Intervention: Whey protein isolate (WPI) supplementation (20 g/d) for 3 months
Number of subjects: 166
Study 29912918 — intervention group
Group type: EXPERIMENTAL
Intervention: Girls-only intervention group
Number of subjects: 259
Study 29912918 — intervention group
Group type: EXPERIMENTAL
Intervention: Mixed-gender intervention group
Number of subjects: 259
Study 29912918 — intervention group
Group type: COMPARATOR
Intervention: Waiting list control group
Number of subjects: 259
Study 26865516 — intervention group
Group type: EXPERIMENTAL
Intervention: Highly malignant EEG (suppression, suppression with periodic discharges, burst‐suppression)
Number of subjects: 202
Study 26865516 — intervention group
Group type: EXPERIMENTAL
Intervention: Any malignant EEG feature
Number of subjects: 202
Study 26865516 — intervention group
Group type: EXPERIMENTAL
Intervention: Two malignant EEG features
Number of subjects: 202
Study 26865516 — intervention group
Group type: EXPERIMENTAL
Intervention: Benign EEG
Number of subjects: 202
Study 24389453 — intervention group
Group type: EXPERIMENTAL
Intervention: Sacha inchi oil (10 or 15ml daily)
Number of subjects: 30
Study 24389453 — intervention group
Group type: COMPARATOR
Intervention: Sunflower oil (10 or 15ml daily)
Number of subjects: 30
Study 24389453 — intervention group
Group type: EXPERIMENTAL
Intervention: Sacha inchi oil and Sunflower oil
Number of subjects: 30
Study 22968159 — intervention group
Group type: EXPERIMENTAL
Intervention: Nebulized hypertonic saline containing hyaluronic acid (Hyaneb)
Number of subjects: 0
Study 22968159 — intervention group
Group type: COMPARATOR
Intervention: Nebulized hypertonic saline solution alone
Number of subjects: 0
Study 19560158 — intervention group
Group type: EXPERIMENTAL
Intervention: Thimerosal-containing vaccines
Number of subjects: 72
Study 17439382 — intervention group
Group type: EXPERIMENTAL
Intervention: Raloxifene
Number of subjects: 89
Study 17439382 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 89
Study 15850499 — intervention group
Group type: EXPERIMENTAL
Intervention: Isradipine (30 mg SR at bedtime, plus 15 mg IR administered 2 h before methamphetamine infusion)
Number of subjects: 18
Study 15850499 — intervention group
Group type: COMPARATOR
Intervention: Placebo (matching placebo)
Number of subjects: 18
Study 12638320 — intervention group
Group type: EXPERIMENTAL
Intervention: Wave intensity (WI) measurement in DCM patients
Number of subjects: 31
Study 12638320 — intervention group
Group type: COMPARATOR
Intervention: Wave intensity (WI) measurement in heart transplant patients
Number of subjects: 31
Study 12638320 — intervention group
Group type: COMPARATOR
Intervention: Wave intensity (WI) measurement in healthy volunteers
Number of subjects: 31
Study 12638320 — intervention group
Group type: EXPERIMENTAL
Intervention: Cardiac output measurement in DCM patients
Number of subjects: 31
Study 12638320 — intervention group
Group type: COMPARATOR
Intervention: Cardiac output measurement in heart transplant patients
Number of subjects: 31
Study 12638320 — intervention group
Group type: EXPERIMENTAL
Intervention: Diastolic heart function assessment in DCM patients
Number of subjects: 31
Study 12638320 — intervention group
Group type: COMPARATOR
Intervention: Diastolic heart function assessment in heart transplant patients
Number of subjects: 31
Study 12638320 — intervention group
Group type: COMPARATOR
Intervention: Diastolic heart function assessment in healthy individuals
Number of subjects: 31
Study 9987143 — intervention group
Group type: EXPERIMENTAL
Intervention: Vi capsular polysaccharide vaccine
Number of subjects: 83